Background The effectiveness of platelet transfusions to prevent bleeding in patients with
hematologic cancers remains unclear. This trial assessed whether a policy of not giving …

Purpose T-cell–replete HLA-haploidentical donor hematopoietic transplantation using post-transplant
cyclophosphamide was originally described using bone marrow (BM). With …

In a multicenter collaboration, we carried out T cell–replete, peripheral blood stem cell (PBSC)
transplantations from related, HLA-haploidentical donors with reduced-intensity …

Relapse remains the most common cause of treatment failure for patients with acute myeloid
leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a …

New transplant approaches are urgently needed for patients with refractory severe aplastic
anemia (SAA) who lack a matched sibling or unrelated donor (UD) or who have failed UD or …

The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders that manifest
as bone marrow failure with the risk of life threatening infections and bleeding. A third of …

4 Responding patients should continue azacitidine until their response is lost. Grade 1A 5
The decision to stop or continue azacitidine in patients who fail to achieve a response after six …

Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have
been classified in the clinically extremely vulnerable group to develop severe acute …

Based on promising results in older adults with acute myeloid leukaemia (AML), we treated
patients with NPM1 mut measurable residual disease (MRD) using off‐label venetoclax in …

Background: There is insufficient evidence to support clinical decision-making for cancer
patients diagnosed with COVID-19 due to the lack of large studies. Methods: We used data …